Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76


Do patient preferences for core outcome domains for chronic gout studies support the validity of composite response criteria?

Taylor WJ, Brown M, Aati O, Weatherall M, Dalbeth N.

Arthritis Care Res (Hoboken). 2013 Aug;65(8):1259-64. doi: 10.1002/acr.21955.


Outcome domains for studies of acute and chronic gout.

Schumacher HR, Taylor W, Edwards L, Grainger R, Schlesinger N, Dalbeth N, Sivera F, Singh J, Evans R, Waltrip RW, Diaz-Torne C, MacDonald P, McQueen F, Perez-Ruiz F.

J Rheumatol. 2009 Oct;36(10):2342-5. doi: 10.3899/jrheum.090370.


Concerns of patients with gout are incompletely captured by OMERACT-endorsed domains of measurement for chronic gout studies.

Diaz-Torne C, Pou MA, Castellvi I, Corominas H, Taylor WJ.

J Clin Rheumatol. 2014 Apr;20(3):138-40. doi: 10.1097/RHU.0000000000000090.


Bringing it all together: a novel approach to the development of response criteria for chronic gout clinical trials.

Taylor WJ, Singh JA, Saag KG, Dalbeth N, MacDonald PA, Edwards NL, Simon LS, Stamp LK, Neogi T, Gaffo AL, Khanna PP, Becker MA, Schumacher HR Jr.

J Rheumatol. 2011 Jul;38(7):1467-70. doi: 10.3899/jrheum.110274.


Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout?

Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E, Schumacher HR Jr.

J Rheumatol. 2001 Mar;28(3):577-80.


A modified Delphi exercise to determine the extent of consensus with OMERACT outcome domains for studies of acute and chronic gout.

Taylor WJ, Schumacher HR Jr, Baraf HS, Chapman P, Stamp L, Doherty M, McQueen F, Dalbeth N, Schlesinger N, Furst DE, Vazquez-Mellado J, Becker MA, Kavanaugh A, Louthrenoo W, Bardin T, Khanna D, Simon LS, Yamanaka H, Choi HK, Zeng X, Strand V, Grainger R, Clegg D, Singh JA, Diaz-Torne C, Boers M, Gow P, Barskova VG.

Ann Rheum Dis. 2008 Jun;67(6):888-91. Epub 2007 Nov 29. Erratum in: Ann Rheum Dis. 2008 Nov;67(11):1652.. Mellado, J Vazquez [corrected to Vazquez-Mellado, J].


Outcome measures for acute and chronic gout.

Schumacher HR Jr, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE, Joseph-Ridge N, Schlesinger N, Horowitz Z, Saag K, Boice JA, Yamanaka H; OMERACT 7 Special Interest Group.

J Rheumatol. 2005 Dec;32(12):2452-5. Review.


Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey.

Khanna PP, Nuki G, Bardin T, Tausche AK, Forsythe A, Goren A, Vietri J, Khanna D.

Health Qual Life Outcomes. 2012 Sep 22;10:117. doi: 10.1186/1477-7525-10-117.


Application of the OMERACT filter to measures of core outcome domains in recent clinical studies of acute gout.

Taylor WJ, Redden D, Dalbeth N, Schumacher HR, Edwards NL, Simon LS, John MR, Essex MN, Watson DJ, Evans R, Rome K, Singh JA.

J Rheumatol. 2014 Mar;41(3):574-80. doi: 10.3899/jrheum.131245. Epub 2014 Jan 15.


Progress in measurement instruments for acute and chronic gout studies.

Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, Schlesinger N, Evans R, Edwards NL, Sivera F, Diaz-Torne C, MacDonald PA, McQueen FM, Schumacher HR.

J Rheumatol. 2009 Oct;36(10):2346-55. doi: 10.3899/jrheum.090371.


Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?

Stamp LK, Khanna PP, Dalbeth N, Boers M, Maksymowych WP, Schumacher HR Jr, Becker MA, MacDonald PA, Edwards NL, Singh JA, Simon LS, McQueen FM, Neogi T, Gaffo AL, Strand V, Taylor WJ.

J Rheumatol. 2011 Jul;38(7):1462-6. doi: 10.3899/jrheum.110273.


Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.

Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.

Curr Med Res Opin. 2009 Jul;25(7):1711-9. doi: 10.1185/03007990903017966.


Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises.

de Lautour H, Taylor WJ, Adebajo A, Alten R, Burgos-Vargas R, Chapman P, Cimmino MA, da Rocha Castelar Pinheiro G, Day R, Harrold LR, Helliwell P, Janssen M, Kerr G, Kavanaugh A, Khanna D, Khanna PP, Lin C, Louthrenoo W, McCarthy G, Vazquez-Mellado J, Mikuls TR, Neogi T, Ogdie A, Perez-Ruiz F, Schlesinger N, Ralph Schumacher H, Scirè CA, Singh JA, Sivera F, Slot O, Stamp LK, Tausche AK, Terkeltaub R, Uhlig T, van de Laar M, White D, Yamanaka H, Zeng X, Dalbeth N.

Arthritis Care Res (Hoboken). 2016 May;68(5):667-72. doi: 10.1002/acr.22741.


Establishing outcome domains for evaluating treatment of acute and chronic gout.

Grainger R, Taylor WJ.

Curr Opin Rheumatol. 2008 Mar;20(2):173-8. doi: 10.1097/BOR.0b013e3282f36cf1. Review.


Outcome evaluations in gout.

Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N, Khanna D, Furst DE, Becker MA, Dalbeth N, Edwards NL.

J Rheumatol. 2007 Jun;34(6):1381-5.


OMERACT endorsement of measures of outcome for studies of acute gout.

Singh JA, Taylor WJ, Dalbeth N, Simon LS, Sundy J, Grainger R, Alten R, March L, Strand V, Wells G, Khanna D, McQueen F, Schlesinger N, Boonen A, Boers M, Saag KG, Schumacher HR, Edwards NL.

J Rheumatol. 2014 Mar;41(3):569-73. doi: 10.3899/jrheum.131246. Epub 2013 Dec 15.


Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials.

Strand V, Khanna D, Singh JA, Forsythe A, Edwards NL.

J Rheumatol. 2012 Jul;39(7):1450-7. doi: 10.3899/jrheum.111375. Epub 2012 Jun 1.


Achieving treat to target in gout: a clinical practice improvement project.

Lim AY, Shen L, Tan CH, Lateef A, Lau TC, Teng GG.

Scand J Rheumatol. 2012;41(6):450-7. doi: 10.3109/03009742.2012.689325. Epub 2012 Jul 28.


Supplemental Content

Support Center